Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UnicoCell Biomed CoTPE:6794 -1.73%79 Cash Ratio is 35.13 as of Jun. 2026, which is 34% above its 10-year median of 26.15. GuruFocus rates TPE:6794 with a GF Score™ of 79/100 and a GF Value™ of NT$65.24 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,383 Biotechnology companies, UnicoCell Biomed Co ranks better than 97.76% on this metric.
UnicoCell Biomed Co has a Cash Ratio of 35.13. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for UnicoCell Biomed Co's Cash Ratio or its related term are showing as below:
TPE:6794'
s Cash Ratio Range Over the Past 10 Years
Min: 6.6 Med: 26.15 Max: 38.57
Current: 35.13
During the past 9 years, UnicoCell Biomed Co's highest Cash Ratio was 38.57. The lowest was 6.60. And the median was 26.15.
TPE:6794's Cash Ratio is ranked better than 97.76% of 1383
companies
in the Biotechnology industry
Industry Median: 2.94
vs TPE:6794: 35.13
UnicoCell Biomed Co (TPE:6794) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
UnicoCell Biomed Co Cash Ratio Related Terms
UnicoCell Biomed Co Cash Ratio Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UnicoCell Biomed Co (TPE:6794) has a Cash Ratio of 35.13 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on UnicoCell Biomed Co and its competitors. This is 34% above median its historical median of 26.15. Over the past decade, UnicoCell Biomed Co's Cash Ratio has ranged from 6.60 to 38.57. According to the industry distribution chart, UnicoCell Biomed Co ranks #31 out of 1383 companies in the Biotechnology industry, placing it in the top 2.2%.
Is UnicoCell Biomed Co's Cash Ratio too high?
UnicoCell Biomed Co's current Cash Ratio of 35.13 is 34% above median its 10-year median of 26.15. Over the past 10 years, this metric has ranged from a low of 6.60 to a high of 38.57. The Biotechnology industry median Cash Ratio is 2.94. UnicoCell Biomed Co's value of 35.13 is 1094.9% above this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #31 out of 1383 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #31 out of 1383 companies for Cash Ratio. This places UnicoCell Biomed Co in the top 2% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.94. UnicoCell Biomed Co's value of 35.13 is 1094.9% above this benchmark. Historically, UnicoCell Biomed Co's own Cash Ratio has ranged from 6.60 to 38.57 over the past decade. While the company's 10-year median is 26.15 vs. the industry median of 2.94, UnicoCell Biomed Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current Cash Ratio of 35.13 is 1094.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current Cash Ratio is 35.13, which is 34% above median its own 10-year median of 26.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$65.24, compared to a current price of NT$73.70 — trading 13% above its estimated fair value. The current Cash Ratio is 35.13, which is 34% above median its 10-year median of 26.15 and 1094.9% above the Biotechnology industry median of 2.94. UnicoCell Biomed Co's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Cash Ratio is 35.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be overvalued.
The current stock price of NT$73.70 is trading 13% above its estimated GF Value™ of NT$65.24.
GuruFocus considers UnicoCell Biomed Co to be Modestly Overvalued.
Key valuation signals for TPE:6794:
Cash Ratio: 35.13 (34% above median its 10-year median of 26.15)
GF Value™: NT$65.24 vs. price of NT$73.70 (13% above fair value)
Industry Position: 1094.9% above the Biotechnology median (#31 of 1383)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
79GF Score
Get the complete analysis for TPE:6794
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
